Beijing Aosaikang Pharmaceutical Co., Ltd. (002755) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Beijing Aosaikang Pharmaceutical Co., Ltd.

Why is Beijing Aosaikang Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -13.15% and Operating profit at -24.69% over the last 5 years

The company has declared positive results for the last 5 consecutive quarters

OPERATING CASH FLOW(Y) Highest at CNY 595.5 MM
NET PROFIT(HY) At CNY 161.78 MM has Grown at 81.91%
ROCE(HY) Highest at 8.29%

With ROE of 6.30%, it has a very expensive valuation with a 6.20 Price to Book Value

Over the past year, while the stock has generated a return of 0.17%, its profits have risen by 691.7% ; the PEG ratio of the company is 0.1
At the current price, the company has a high dividend yield of 0.6

Underperformed the market in the last 1 year

The stock has generated a return of 0.17% in the last 1 year, much lower than market (China Shanghai Composite) returns of 24.70%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Beijing Aosaikang Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beijing Aosaikang Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Beijing Aosaikang Pharmaceutical Co., Ltd.

0.17%

1.72

47.45%

China Shanghai Composite

24.7%

1.91

12.94%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.15%

EBIT Growth (5y)

-24.69%

EBIT to Interest (avg)

51.75

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.71

Sales to Capital Employed (avg)

0.54

Tax Ratio

12.41%

Dividend Payout Ratio

69.48%

Pledged Shares

Institutional Holding

ROCE (avg)

13.28%

ROE (avg)

7.19%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

6.20

EV to EBIT

99.09

EV to EBITDA

60.35

EV to Capital Employed

20.94

EV to Sales

9.34

PEG Ratio

0.14

Dividend Yield

0.57%

ROCE (Latest)

21.13%

ROE (Latest)

6.30%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 595.5 MM

NET PROFIT(HY)

At CNY 161.78 MM has Grown at 81.91%

ROCE(HY)

Highest at 8.29%

DEBT-EQUITY RATIO (HY)

Lowest at -75.59 %

CASH AND EQV(HY)

Highest at CNY 4,847.97 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.5 times

-2What is not working for the Company

RAW MATERIAL COST(Y)

Grown by 6.57% (YoY

NET SALES(Q)

At CNY 426.48 MM has Fallen at -8.41%

Here's what is working for Beijing Aosaikang Pharmaceutical Co., Ltd.

Operating Cash Flow

Highest at CNY 595.5 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Profit

At CNY 161.78 MM has Grown at 81.91%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Debt-Equity Ratio

Lowest at -75.59 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Cash and Eqv

Highest at CNY 4,847.97 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 2.5 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Beijing Aosaikang Pharmaceutical Co., Ltd.

Net Sales

At CNY 426.48 MM has Fallen at -8.41%

over average net sales of the previous four periods of CNY 465.62 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Raw Material Cost

Grown by 6.57% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales